Martin Babler, Alumis CEO
June 28, 2024 06:15 AM EDTUpdated 04:31 PM
Financing
Startups

Im­munol­o­gy biotech Alu­mis se­cures $250M in shrunk­en IPO

Kyle LaHucik

Senior Reporter

Alu­mis, an im­munol­o­gy drug de­vel­op­er on the cusp of Phase 3, will go pub­lic Fri­day in a small­er IPO than it orig­i­nal­ly pro­ject­ed.

The Bay …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Al­ny­lam’s RNAi ther­a­py suc­ceeds in close­ly-watched Phase 3 heart tri­al

A service from the Financial Times